Form 4: Vir Biotechnology Director Robert Nelsen Reports Share Acquisition and Option Grant

Director Robert Nelsen reported the acquisition of 8,000 common stock shares and a grant of 16,000 stock options in Vir Biotechnology, Inc.

Summary

• Robert Nelsen, a director of Vir Biotechnology, Inc., filed a Form 4 detailing changes in his beneficial ownership.
• On May 30, 2024, Nelsen acquired 8,000 shares of common stock at $0 and was granted options to purchase 16,000 shares.
• Following these transactions, Nelsen directly owns 584,148 shares of common stock.
• He also has indirect ownership through ARCH Venture Fund IX, L.P. (5,626,008 shares), ARCH Venture Fund IX Overage, L.P. (7,290,655 shares), and a family trust (33,893 shares).
• The stock options have an exercise price of $10.39, are exercisable from May 30, 2025, and expire on May 29, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and option grant could be seen as mildly positive, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the director's holdings and incentives.
• The acquisition of shares by a director may influence investor sentiment.

Key Dates